MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +47.31%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.48 per share when it actually produced earnings of $0.27, delivering a surprise of +156.25%.Over the last four quarters, the ...